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Abstract
DNAzymes are still fairly recent man-made additions to the growing spectrum of
synthetic molecules dramatically advancing the field of biomolecular science. These
catalytically active nucleic acids have great potential in personalized medicine
and as internal biosensors owing to their low immunogenicity, as well as in
bio-computing, because of their robust nature and large data storage capacity.
Their future potential is evident in areas that range from the development of biofuel
cells to power implanted electronics, like pacemakers, where they could exceed
capabilities and circumvent obstacles of existing protein-based catalysis.
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Introduction
Since their synthesis in 1994 [1] DNA-based enzymes have evolved into an exciting area of
biochemistry, molecular biotechnology and bio-computing. The catalytic activity of short
stranded nucleic acids was first discovered over thirty years ago when naturally occurring
ribonucleic acid (RNA) molecules were discovered to act as catalysts in reactions such
as phosphodiester bond hydrolysis, thus named ribozymes [2]. Translation of RNA into
protein is accomplished by a ribozyme in the active center of cellular ribosomes [3]. Most
RNAs are relatively unstable molecules, as their intended use only requires short lifespans
in vivo, while their transcriptional origin, the deoxyribonucleic acid (DNA) is far more
robust, rendering DNA a more suitable molecule for most approaches [1]. As known to
date, nature has not generated catalytically active DNA in vivo to the extent it has with
RNA-based ribozymes [1], yet Mankind succeeded in developing catalytically active short
stranded oligonucleotides termed deoxyribozymes or DNAzymes synthetically [1]. While
DNAzymes are currently not utilized in commercial applications, the fundamental research
behind their capabilities is abundant [1,2,4-6]. The primary use for DNAzymes lies in the
manipulation of nucleic acids, whether it be their cleavage [1] or ligation [4]; however, more
atypical uses have been found, including the reaction of metal ions with porphyrin rings
[7]. Much like traditional protein enzymes, DNAzymes exhibit a high level of selectivity
and specificity. This is intrinsically a result of their construction from nucleic acids: small
molecules notorious for their exceptionally elevated specificity and selectivity to their
given conjugate base pair [8]. DNAzymes present advantages over traditional enzymes.
DNA is well-known for its long-term stability at a wide range of temperatures and is even
considered an attractive alternative for long-term data storage [9], whereas protein-based
enzymes are typically more sensitive to fluctuations in temperature, and could undergo
undesired conformational changes or denaturation. Furthermore the ability of DNA to be
stored in a dry state allows for a much higher level of convenience when dealing with the
transportation and distribution of DNAzyme-based technologies [10]. Following this logic,
DNAzymes have been immobilized on electronic transducers [11] and nanoparticles [12]
for use in detection systems, for bio-computing architectures and for their use as molecular
switches in signal amplification [13]. The lack of naturally occurring DNAzymes in vivo,
requires their synthesis in vitro. However, prior to mass-production of any DNAzyme, a
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desirable catalytic activity and target specificity must be confirmed. Therefore, libraries
with large populations of fixed-length random sequence oligonucleotides are generated
and screened for their interaction with a compound of interest via Systematic Evolution of
Ligands by Exponential Enrichment (SELEX) [8]. Purified ligated compounds are typically
isolated and amplified by PCR to generate a large quantity of highly specific DNAzymes
[14]. Recently it has been shown that enzyme function can be achieved by molecular in
vitro evolution from a non-catalytic sequence, leading to a DNAzyme with RNA cleavage
properties [15].
Applications of DNAzymes
DNAzymes in Cancer Treatment
Since their development, DNAzymes have been used for a variety of applications. One
of their greatest potentials within the medical research community is the manipulation
and silencing of RNA pathways for the inhibition of gene expression, typically for use in
cancer therapy. With this in mind, a “general purpose” RNA-cleaving Mg2+ dependent
DNAzyme was synthesized [16]. This DNAzyme, called 10-23 DNA Enzyme, consists
of two substrate-recognition domains of approximately eight bases separated by a 15
nucleotide catalytic domain. The domain-recognition “arms” can be tailored to any set of
complimentary RNA bases, resulting in the catalyzed cleavage of mRNA. In this context,
a promising use for DNAzymes could lie in targeting osteosarcoma at the source [17].
Osteosarcoma is a debilitating cancer typically weakening the bones of adolescents and
young-adults and commonly metastasizing to the lungs [18]. Most cases of high-grade
osteosarcoma are found to have increased expression of c-jun, a proto-oncogene [19,20]. The
DZ13 DNAzyme catalyzed gene silencing could stimulate apoptosis of osteosarcoma cells
by the down-regulation of c-jun mRNA [18,19,21,22], while having no adverse effect on cell
proliferation of non-osteosarcoma cells. The first clinical trial in humans for the treatment
of basal cell carcinoma (BCC) with DZ13 successfully completed Phase 1, showing decreased
expression of c-jun in patients with nodular BCC, while no drug-related serious side effects
were reported [23]. These promising results could pave the way for the use of DNAzyme
DZ13 as a cancer treatment drug for controlled apoptosis of cancer cells with obvious and
significant implications for future cancer treatments [17].
DNAzymes in Bio-computing Systems
Aside from their application in cancer therapy, DNAzymes have been used extensively in
the realm of bio-computing. Contrary to popular belief, a vast majority of bio-computing
does not aim to compete as an alternative to modern silicon computing. Rather,
bio-computation focuses on the development of architectures for interfacing existing
computing motifs with living systems in biological environments. This is typically in
the form of chemical and biochemical interface systems that can directly interact with
biomolecules, but also communicate with digital systems through optical or electric
measurements [24]. One line of focus lies in the creation of systems capable of performing
various Boolean logic operations, from relatively simple realizations such as AND and
OR [25-28] to more complicated architectures including XOR, NOR, NAND, INHIB, and
XNOR [29-42]. These Boolean logic motifs can then be integrated into larger autonomous
“physio-diagnostic” devices, capable of real-time monitoring of living systems with built-in
logic [43]. These bio-computing devices are often realized using enzymes, and similar
biomolecules capable of direct interaction with biological systems [44-47]. Horseradish
peroxidase (E.C. 1.11.1.7) is an enzyme frequently used in bio-computing owing to its ability
to oxidize common redox species and to participate in colorimetric reactions [48]. Therefore,
it is logical that this would be one of the first characteristics that researchers attempted to
mimic using DNAzymes. This was successfully done with the development of a guanine-rich
DNAzyme, capable of complexing with a hemin molecule for the catalysis of the oxidation
of common redox species, such as 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
(ABTS), in the presence of hydrogen peroxide [49,50]. When presented with a specifically
programmed mRNA scaffold and a hemin molecule the activity of this DNAzyme was
activated, allowing for the controllable oxidation of photoactive redox dyes, such as ABTS.
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This is essential to bio-computing, because almost all bio-computation motifs include a
final step resulting in the controlled oxidation or reduction of a dye. This allows for both
qualitative and quantitative results to be measured, or for the storage of information in the
case of memory units [48].
Conclusions and Future Perspectives
With small molecule gene silencing strategies on the rise, DNAzymes have great potential
as therapeutic agents. The apparent lack of off-target effects commonly seen in higher
organisms for gene silencing approaches using antisense and siRNA, is possibly a result
of the self-sufficient cleavage properties of DNAzymes, whereas siRNAs operate via the
cell endogenous Dicer/RISC mechanism [51]. Sequence composition induced interferon
responses common to antisense RNA mediated long double-stranded RNA molecules,
which cause a more global mRNA degeneration in mammals [52] have not been described
for DNAzymes so far. Nevertheless, similar to any establishment of siRNA mediated gene
knockdown, a range of molecules might need to be tested to achieve optimal target RNA
cleavage and control experiments using a randomized sequence flanking the catalytic core
instead of the target binding sequence are imperative. Toxic effects due to the use of cationic
lipofectants as DNAzyme delivery method have been described [53]. Since DNAzymes
act through selective binding and cleavage of mRNA, this method, like all gene silencing
approaches will merely achieve a knockdown of mRNA transcripts. Therefore unlike classic
and conditional gene targeting by homologous recombination [54] DNAzymes might be
limited in modeling gene function and disease, depending on the relevance of the target
gene or when a complete loss-of function approach is crucial. The potential risk of DNA
mediated mutagenesis due to random integration of foreign DNA fragments into the host
genome is further to be considered when using DNAzymes as therapeutic agent. While
DNA is generally more stable than ribonucleic acids, DNAzymes, too, are vulnerable to
exonuclease-mediated degradation, and might therefore require direct delivery to a target
cell. This could exclude DNAzymes from the treatment of pathophysiological conditions
where bioavailability is challenging due to difficulties in DNAzyme delivery or impaired
cellular uptake thereof. Similar to work with antisense oligonucleotides, ribozymes and
aptamers, modifications to increase DNAzyme half-life for in vivo applications have been
explored [53,55-58]. Phosphorothioate modifications to confer endonuclease resistance as
commonly used in ribozymes and aptamers inflict a similar toxic and off-target effect when
used in DNAzymes [59-62]. Other modifications, like terminal stem-loop hairpins of the
substrate binding arms [63] or a 3’-3’ inverted nucleotide at the 3’terminus of the DNAzyme
molecule [57] appear promising. With the continued development of advanced artificial
biomolecular motifs, such as DNAzymes, bio-computational and biomedical architectures,
solutions previously only envisioned in science fiction writings, become more realistic.
The potential for bio-catalytic species, like traditional protein enzymes, produced from
highly specific and robust components, like DNA, is limitless. One obvious field that could
be significantly impacted is that of biofuel cell technologies. Typically constructed from
redox enzymes or nanoparticles, biofuel cells utilize their catalytic nature to extract energy
from their surroundings [43]. One of the most potentially hopeful of these circumstances
is the implantation in animals and humans, where glucose and oxygen are typically used
as “fuel”. The goal is for this harvested energy to be used to power implanted electronics,
such as pacemakers [64]. One of the greatest limitations facing modern implantable biofuel
cells is the long-term stability of the enzymes immobilized on their surface. If DNAzymes
were developed that were capable of the bio-catalytic redox catalysis of glucose and oxygen,
the most common sources of fuel for implantable biofuel cells [43], future biofuel cell
electrodes could be developed with the ability to outlast even the most robust protein-based
enzyme electrodes. Future applications for DNAzymes in cancer treatment are apparent,
and steps have been taken towards their realization. Continued research and interest in
this field could result in a highly specific and effective DNAzyme-based anti-tumor cell
treatment. Given the high specificity of DNAzymes, treatments could be tailored to specific
mutations of a cancer cell; for example by targeting specific nucleotide sequences that
result in cancerous characteristics and therefore distinguish the cancer cell from healthy
neighbors. Additionally, being composed of bare DNA, DNAzymes inherently represent a
minimal risk of unintended toxicity, unlike current chemotherapy compounds. This being
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said, any technology involving the direct interaction with a host cell’s nucleic acids must
be carefully tested and regulated to ensure its safety by minimizing off-target effects. No
cancer treatment would be beneficial to any patient if the induction of apoptosis would not
be tumor cell-specific. DNAzymes show promising potential in many other areas aside from
the ones mentioned above. Whenever targeting at a molecular level is required, DNAzymes
might be of use, for example in targeting RNAs encoding viral structures causative of
human immunodeficiency virus infection (HIV) [65], dengue fever [66], “bird flu” (H1N1
and related strains) [67], severe acute respiratory syndrome (SARS) [68] and more recent
threats to society like the middle east respiratory syndrome (MERS) or Ebola. DNAzymes
could provide a novel option in such areas desperate for urgent solutions. Treatment with
DNAzyme DZ1 targeting the late membrane protein 1 (LPM1) of the Epstein Barr virus, an
oncogenic factor thought as major contibutor in nasopharyngeal carcinoma (NPC) showed
increased radiosensitivity and decreased angiogenesis in LPM1-induced NPC [69]. Another
clinical trial to test the efficacy and safety of the DNAzyme SB010 in allergen-induced
asthmatic responses aiming at silencing GATA3 was also recently completed [70] , while
trials for a topical application of SB011 to treat mild to moderate atopic dermatitis as well
as intrarectally applied SB012 to treat active ulcerative colitis are currently recruiting
(www.ClinicalTrials.gov). Technological advances allow for further fine tuning of the
activity of DNAzymes by using a L-ribose (L-RNA) sugar backbone instead of the naturally
occurring D-ribose (D-RNA) [71,72]. This has the potential to overcome current obstacles for
broader implications of DNAzymes in bioanalytical, therapeutic or diagnostic applications
hampered by RNAse-mediated substrate degradation in complex biological samples [72].
In combination with a low immunogenicity of DNAzymes and high precision at a nucleic
acid base level, DNAzymes have the potential to excel in personalized medicine just as much
as in biofuel cell technologies. Future combined efforts of biomolecular, biochemical and
bioinformatic sciences improving DNAzymes and identifying more possible targets and
applications will also impact on the evolving field of Synthetic Biology [6,73] (see Figure
1).
Cancer	  	  
Treatment	   Treatment	  




















Figure 1: Multidisciplinary efforts make way for current and future applications for DNA Enzyme Systems in the
medical and biotechnological fields. (DNAzyme schematic adapted from [74])
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